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Aurora kinases are key players in ensuring accurate chromosome segregation during the cell cycle, maintaining genetic integrity in cell division. 2 Over the last few years, much attention has been focused on the involvement of these proteins in the process of tumorigenesis. High Aurora-B and Aurora-A expression has been reported in various types of commonly occurring malignancy and, in some cases, correlated with aneuploidy and poor prognosis. Despite the many reports of high expression of Aurora-B and Aurora-A in solid tumors, 3, 4 information regarding expression in hematologic malignancies is still limited, 5, 6, 7 especially in MDS. Our study included 61 MDS patients, 31 male and 30 female (median age 66 years; range 15-91 years). According to WHO classification, there were 6 patients with refractory anemia (RA), 2 patients with refractory neutropenia (RN), 2 patients with isolated del(5q), 9 patients with ring sideroblasts (RARS), 28 patients with refractory cytopenia with multilineage dysplasia (RCMD), 3 patients with RA with excess of blasts 1 (RAEB-1), 5 patients with RA with excess of blasts 2 (RAEB-2), and 6 patients with therapy-related MDS. Four samples from healthy volunteers were used as controls. Among these patients, 85% were stratified as low risk and 15% as high risk according to IPSS.
Total RNA from MDS patients and donor bone marrow cells were isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA). To analyze aurora kinases genes, TaqMan Assays were used (Aurora-A: Hs00269212_m1 and Aurora-B: Hs00177782_m1; Applied Biosystems). β2-microglobulin (B2M: Hs99999907_m1) and Ubiquitin C (UBC: Hs00824723_m1) were chosen as endogeneous internal control for each sample. The comparative cycle threshold (Ct) method was used to determine the relative expression levels of Aurora-B and Aurora-A genes. Their haematologica 2012; 97:e37 Although many studies have reported high expression of Aurora-B and Aurora-A in solid and hematologic cancers, in our study we did not find any association between clinical or laboratory features with prognostic impact (number of cytopenias, cytogenetic abnormalities, transfusion dependency, WHO classification and IPSS group) and the expression of both Aurora-B and Aurora-A kinases.
LETTERS TO THE EDITOR
Recently, Lucena-Araujo et al. 5 showed a significant association between high expression of Aurora-A and unfavorable cytogenetics in AML patients, but not with 6 analyzed 20 patients with MDS and did not detect any significant correlation of Aurora-A gene expression with bone marrow blast counts, viability of CD34 + blast cells, cytogenetic abnormalities or IPSS score.
Our study included a good representative number of lower risk patients and this may have contributed to the absence of any statistical difference among groups (Table  2) . However, no difference was found when only the lower risk groups (RA, RARS, RCMD) were compared, in contrast to that reported by Yoshida et al. 1 One possible explanation for these different results could be related to the genetic variation between study populations. Some studies showed that the difference in the incidence of chromosomal abnormalities in MDS patients varies according to the group under study (low vs. high risk), with possible geographical and ethnic influences. 8 According to the Brazilian National MDS Register, 9 Magalhaes observed significant differences between other American, European and Asian reports, and even between Brazilian geographical regions; indicating that racial miscegenation might play a role.
Despite the limited information regarding the expression of Aurora-B kinase in hematologic malignancies, our data suggest that Aurora-B expression may not have a prognostic significance in MDS patients, as shown in other tumors. This may reflect the heterogeneous presentation of MDS and the diversity of the mechanisms involved in its pathogenesis. 
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